PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Zhao, A.* ; Gudmundsson, E.* ; Mogulkoc, N.* ; van Moorsel, C.* ; Corte, T.J.* ; Vasudev, P.* ; Romei, C.* ; Chapman, R.* ; Wallis, T.J.M.* ; Denneny, E.* ; Goos, T.* ; Savas, R.* ; Ahmed, A.* ; Brereton, C.J.* ; van Es, H.W.* ; Jo, H.* ; De Liperi, A.* ; Duncan, M.* ; Pontoppidan, K.* ; De Sadeleer, L.J. ; van Beek, F.* ; Barnett, J.* ; Cross, G.* ; Procter, A.* ; Veltkamp, M.* ; Hopkins, P.* ; Moodley, Y.* ; Taliani, A.* ; Taylor, M.* ; Verleden, S.* ; Tavanti, L.* ; Vermant, M.* ; Nair, A.* ; Stewart, I.* ; Janes, S.M.* ; Young, A.L.* ; Barber, D.* ; Alexander, D.C.* ; Porter, J.C.* ; Wells, A.U.* ; Jones, M.G.* ; Wuyts, W.A.* ; Jacob, J.*

Mortality surrogates in combined pulmonary fibrosis and emphysema.

Eur. Respir. J. 63:2300127 (2023)
Postprint DOI PMC
Open Access Green
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) with co-existent emphysema, termed combined pulmonary fibrosis and emphysema (CPFE) may associate with reduced forced vital capacity (FVC) declines compared to non-CPFE IPF patients. We examined associations between mortality and functional measures of disease progression in two IPF cohorts. METHODS: Visual emphysema presence (>0% emphysema) scored on computed tomography identified CPFE patients (CPFE:non-CPFE: derivation cohort=317:183; replication cohort=358:152), who were subgrouped using 10%, or 15% visual emphysema thresholds, and an unsupervised machine learning model considering emphysema and ILD extents. Baseline characteristics, 1-year relative FVC and diffusing capacity of the lung for carbon monoxide (DLco) decline (linear mixed-effects models), and their associations with mortality (multivariable Cox regression models) were compared across non-CPFE and CPFE subgroups. RESULTS: In both IPF cohorts, CPFE patients with ≥10% emphysema had a greater smoking history and lower baseline DLco compared to CPFE patients with <10% emphysema. Using multivariable Cox regression analyses in patients with ≥10% emphysema, 1-year DLco decline showed stronger mortality associations than 1-year FVC decline. Results were maintained in patients suitable for therapeutic IPF trials and in subjects subgrouped by ≥15% emphysema and using unsupervised machine learning. Importantly, the unsupervised machine learning approach identified CPFE patients in whom FVC decline did not associate strongly with mortality. In non-CPFE IPF patients, 1-year FVC declines ≥5% and ≥10% showed strong mortality associations. CONCLUSION: When assessing disease progression in IPF, DLco decline should be considered in patients with ≥10% emphysema and a ≥5% 1-year relative FVC decline threshold considered in non-CPFE IPF patients.
Impact Factor
Scopus SNIP
Altmetric
24.300
0.000
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Survival
Sprache englisch
Veröffentlichungsjahr 2023
HGF-Berichtsjahr 2023
ISSN (print) / ISBN 0903-1936
e-ISSN 1399-3003
Zeitschrift European Respiratory Journal
Quellenangaben Band: 63, Heft: 4, Seiten: , Artikelnummer: 2300127 Supplement: ,
Verlag European Respiratory Society
Verlagsort Sheffield
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Lung Health and Immunity (LHI)
POF Topic(s) 30202 - Environmental Health
Forschungsfeld(er) Lung Research
PSP-Element(e) G-501693-001
Förderungen Roche Products Pty Ltd.
Boehringer Ingelheim
CSC-UCL Joint Research Scholarship
NIHR Southampton Biomedical Research Centre
NIHR UCLH Biomedical Research Centre, UK
Wellcome Trust
DOI 10.1183/13993003.00127-2023
WOS ID 001208899300007
Scopus ID 85190175366
PubMed ID 37973176
Erfassungsdatum 2023-11-28
[➜Korrektur melden]